Literature DB >> 31356198

Overexpression of CrkL as a novel biomarker for poor prognosis in gastric cancer.

Runhua Feng1,2,3, Jianfang Li2,3, Birendra K Sah1, Fei Yuan4, Xiaolong Jin4, Min Yan1, Bingya Liu2,3, Chen Li1,2,3, Zhenggang Zhu1,2,3.   

Abstract

BACKGROUND: The signaling adapter protein CrkL plays vital roles in multiple cancers. However, the expression pattern of CrkL protein and its clinical significance have not been well characterized in human gastric cancer (GC) so far.
OBJECTIVE: To investigate the association of tissue-based CrkL protein expression level with the clinicopathological characteristics and prognosis of GC patients.
METHODS: The expression level of CrkL protein in 380 GC patients was analyzed by immunohistochemistry. The associations of CrkL protein expression level with clinicopathologicalal characteristics and clinical outcome were evaluated.
RESULTS: Compared with the matched adjacent non-tumor tissues, CrkL protein expression level was significantly up-regulated in tumor tissues. In addition, there was a positive correlation between CrkL and Ki67 expression levels in GC patients. An elevated CrkL level statistically correlated with aggressive clinicopathologicalal characteristics, such as larger tumor size, deeper local invasion, more lymph node metastasis, advanced TNM stage, and poorer prognosis. Notably, multivariate analysis identified tissue-based CrkL level as an independent predictor for the unfavorable prognosis of GC.
CONCLUSIONS: These results indicate that CrkL protein may serve as a novel prognostic biomarker in GC.

Entities:  

Keywords:  CrkL; Gastric cancer; immunohistochemistry; prognosis; tumorigenesis

Mesh:

Substances:

Year:  2019        PMID: 31356198     DOI: 10.3233/CBM-192435

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  2 in total

1.  CRKL is a critical target of Hh-GLI2 pathway in lung adenocarcinoma.

Authors:  Xiaoming Liu; Yan Hu; Bentong Yu; Kai Peng; Xin Gan
Journal:  J Cell Mol Med       Date:  2021-06-02       Impact factor: 5.310

2.  Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.

Authors:  Jiang Yu; Wen-Xu Chen; Wen-Jing Xie; Rong-Wei Chen; Dan-Qi Lin; Wei-Wei You; Wei-Lin Ye; Hong-Qin Zhang; Dong-Hong Lin; Jian-Ping Xu
Journal:  J Clin Lab Anal       Date:  2021-06-11       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.